BR112017013420A2 - anticorpo adam17 humanizado - Google Patents

anticorpo adam17 humanizado

Info

Publication number
BR112017013420A2
BR112017013420A2 BR112017013420A BR112017013420A BR112017013420A2 BR 112017013420 A2 BR112017013420 A2 BR 112017013420A2 BR 112017013420 A BR112017013420 A BR 112017013420A BR 112017013420 A BR112017013420 A BR 112017013420A BR 112017013420 A2 BR112017013420 A2 BR 112017013420A2
Authority
BR
Brazil
Prior art keywords
humanized antibody
adam17
humanized
antibody
binding
Prior art date
Application number
BR112017013420A
Other languages
English (en)
Inventor
Tesar Michael
Lowe Peter
berger Sven
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of BR112017013420A2 publication Critical patent/BR112017013420A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

a presente invenção se relaciona a um novo anticorpo humanizado capaz de se ligar a adam17, e também as sequências de amino e ácido nucleico que codificam para referido anticorpo. de um aspecto, a invenção se relaciona a um novo anticorpo humanizado, ou fragmentos de ligação de antígeno, capazes de se ligarem a adam17 com atividades antitumor. a invenção também compreende o uso de referido anticorpo humanizado como um fármaco para o tratamento de câncer. finalmente, a invenção compreende composições compreendendo referido anticorpo humanizado, sozinho, ou em combinação ou conjugação com outros compostos anticâncer, e ao uso do mesmo para o tratamento de câncer.
BR112017013420A 2014-12-24 2016-01-04 anticorpo adam17 humanizado BR112017013420A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14307185 2014-12-24
PCT/EP2016/050029 WO2016102716A1 (en) 2014-12-24 2016-01-04 Novel humanized adam17 antibody

Publications (1)

Publication Number Publication Date
BR112017013420A2 true BR112017013420A2 (pt) 2018-02-06

Family

ID=52396391

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017013420A BR112017013420A2 (pt) 2014-12-24 2016-01-04 anticorpo adam17 humanizado

Country Status (11)

Country Link
US (1) US20180057601A1 (pt)
EP (1) EP3237008A1 (pt)
JP (1) JP2018502096A (pt)
KR (1) KR20170099927A (pt)
CN (1) CN107250162A (pt)
AU (1) AU2016204625A1 (pt)
BR (1) BR112017013420A2 (pt)
CA (1) CA2971361A1 (pt)
MX (1) MX2017008475A (pt)
RU (1) RU2017125036A (pt)
WO (1) WO2016102716A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020021061A1 (en) 2018-07-26 2020-01-30 Pieris Pharmaceuticals Gmbh Humanized anti-pd-1 antibodies and uses thereof
DE102018124785A1 (de) 2018-10-08 2020-04-09 Schott Ag Glas mit vorzugsweise erhöhter speicherbarer Zugspannung, chemisch vorgespannter Glasartikel mit vorzugsweise erhöhter speicherbarer Zugspannung, Verfahren zu dessen Herstellung sowie dessen Verwendung

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001036445A1 (en) * 1999-11-18 2001-05-25 The Brigham And Women's Hospital, Inc. Compositions and methods for the improved diagnosis and treatment of germ cell tumors
EP1449538A1 (en) * 2003-02-21 2004-08-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibition of TACE or amphiregulin for the modulation of EGF receptor signal transactivation
EP1833964B1 (en) * 2004-12-17 2013-05-22 Monash University Regulation of metalloprotease cleavage of cell surface proteins by adam10
CN103492413A (zh) * 2011-02-01 2014-01-01 癌症研究技术有限公司 抗tace抗体分子及其应用
EP3495470A1 (en) * 2011-06-29 2019-06-12 The General Hospital Corporation In vivo methods for enhancing bioenergetic status in female germ cells
WO2014157229A1 (ja) * 2013-03-28 2014-10-02 国立大学法人東北大学 Ｔａｃｅペプチドエピトープ、抗ヒトｔａｃｅタンパク質抗体及び当該抗体を産生するハイブリドーマ

Also Published As

Publication number Publication date
US20180057601A1 (en) 2018-03-01
AU2016204625A1 (en) 2017-07-13
CA2971361A1 (en) 2016-06-30
MX2017008475A (es) 2018-02-21
KR20170099927A (ko) 2017-09-01
CN107250162A (zh) 2017-10-13
WO2016102716A1 (en) 2016-06-30
JP2018502096A (ja) 2018-01-25
EP3237008A1 (en) 2017-11-01
RU2017125036A (ru) 2019-01-24

Similar Documents

Publication Publication Date Title
PH12018500233A1 (en) Single domain antibody programmed death-ligand (pd-l1) and derived protein thereof
PH12018502112A1 (en) Anti-tim-3 antibodies and compositions
PH12017500890A1 (en) Antibody drug conjugates
GEP20237466B (en) Methods of inhibiting angiogenesis in patient
BR112015003757A2 (pt) anticorpos e vacinas para uso no tratamento de cânceres de ror1 e inibição de metástase
PH12017500002A1 (en) Anti-cdh6 antibody drug conjugates
EA202091540A1 (ru) Антитела к lilrb2
TN2015000396A1 (en) Antibody drug conjugates
MX2018000147A (es) Moleculas de anticuerpo que se unen al grupo de diferenciacion 45 (cd45).
BR112017010324A2 (pt) método para tratar ou retardar a progressão de um câncer em um indivíduo, moléculas, métodos para aumentar a função imune em um indivíduo e para selecionar um paciente para tratamento, kits, composição farmacêutica e usos de uma combinação de uma molécula
MX2018002166A (es) Conjugados anticuerpo anti-dll3-farmaco y metodos de uso.
MX2014015830A (es) Anticuerpos lsr y usos de los mismos para el tratamiento de cancer.
MX2018010295A (es) Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
EA201992251A1 (ru) Противораковые вакцины и способы лечения с их применением
MX2014009289A (es) Anticuerpos c1orf32 y usos de los mismos para el tratamiento del cancer.
PH12016502061A1 (en) Novel antii-rnf43 antibodies and methods of use
MX2018006249A (es) Nuevos anticuerpos anti-emr2 y metodos de uso.
MX2021002144A (es) Anticuerpo igf-1r y su uso como un vehiculo con especificidad de objetivo para el tratamiento contra el cancer.
MX2022000242A (es) Anticuerpos contra ticagrelor y metodos de uso.
MX2019015527A (es) Conjugados y composiciones de texafirina-pt (iv) para su uso para superar la resistencia del platino.
MX2018007817A (es) Nuevos anticuerpos anti-mmp16 y metodos para su uso.
BR112017013420A2 (pt) anticorpo adam17 humanizado
MX2016008478A (es) Nuevo anticuerpo anti adam17 y su uso en el tratamiento del cancer.
MA40363A (fr) Agents de liaison de rspo1 et leurs utilisations

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]